Holen Sie sich die Stockscreener-App
27.19
0.59%
0.16
Handel nachbörslich:
26.91
-0.28
-1.03%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt ALKS?
Forum
Prognose
Aktiensplit
Alkermes Plc Aktie (ALKS) Neueste Nachrichten
Goldman Sachs Initiates Alkermes (ALKS) with a Buy Rating - MSN
What analysts say about Alkermes plc stockHigh-yield portfolio picks - Autocar Professional
Alkermes plc (NASDAQ:ALKS) Launches Phase II Trial of ALKS 2680 for Idiopathic Hypersomnia - MSN
Alkermes plc Stock Analysis and ForecastSuperior investment outcomes - jammulinksnews.com
What drives Alkermes plc stock priceConsistently exceptional gains - Autocar Professional
Is Alkermes plc a good long term investmentFree Wealth Planning Blueprint - jammulinksnews.com
Alkermes (ALKS) Expected to Beat Earnings Estimates: Should You Buy? - Yahoo Finance
ALKS Down Despite Positive Top-Line Data From Narcolepsy Study - Yahoo Finance
Alkermes Announces Positive Phase 2 Study Results - TipRanks
Alkermes To Advance Alixorexton After Positive Phase II Narcolepsy Results - insights.citeline.com
Jefferies Raises Target for Alkermes (ALKS) Following Promising Drug Data | ALKS Stock News - GuruFocus
Alkermes Offers The Next Proof Point For Its Narcolepsy Approach. Stock Dives. - inkl
Alkermes Oral Drug Helps Patients Stay Awake In Mid-Stage Sleep Disorder Study - inkl
Alkermes narcolepsy drug headed for late-stage testing - BioPharma Dive
Needham & Company LLC Reaffirms Buy Rating for Alkermes (NASDAQ:ALKS) - MarketBeat
Alkermes stock rating reiterated as Buy by Stifel after positive narcolepsy data - Investing.com UK
Alkermes Vibrance-1 Phase 2 Study Of Alixorexton In Narcolepsy Type 1 Meets Primary Goal - Nasdaq
Alkermes announces positive topline results from Vibrance-1 Phase 2 study - MarketScreener
Alkermes narcolepsy drug shows positive results in phase 2 trial By Investing.com - Investing.com UK
Alkermes Announces Positive Topline Results From Vibrance-1 Phase 2 Study of Once-Daily Alixorexton in Patients With Narcolepsy Type 1 - PR Newswire
Is Alkermes Plc's (NASDAQ:ALKS) Latest Stock Performance Being Led By Its Strong Fundamentals? - 富途牛牛
10 Most Undervalued Pharma Stocks To Buy Now - Insider Monkey
BlackRock increases stake in Alkermes to 17.05% By Investing.com - Investing.com India
BlackRock increases stake in Alkermes to 17.05% - Investing.com
Alkermes to Release Q2 Financial Results on July 29, 2025 - AInvest
Alkermes to Report Second Quarter Financial Results on July 29, 2025 - MarketScreener
Expert Outlook: Alkermes Through The Eyes Of 6 Analysts - Benzinga
Goldman Sachs Initiates Coverage on Alkermes (ALKS) with a Buy R - GuruFocus
How Much Upside is Left in Alkermes (ALKS)? Wall Street Analysts Think 33.19% - Yahoo Finance
(ALKS) Pivots Trading Plans and Risk Controls - news.stocktradersdaily.com
Alkermes (NASDAQ:ALKS) shareholders have earned a 9.3% CAGR over the last five years - simplywall.st
INVESTOR ALERT: Levi & Korsinsky, LLP Reminds Shareholders of Alkermes plc of a Class Action Lawsuit and a Lead Plaintiff Deadline of January 22, 2018ALKS - ACCESS Newswire
Zacks Industry Outlook Highlights Exelixis, Verona Pharma, Alkermes, Kiniska Pharmaceuticals and Immunocore - Yahoo Finance
Alkermes plc(NasdaqGS: ALKS) added to Russell 2500 Value Index - MarketScreener
Alkermes spinoff Mural plunges on plans to halt ovarian cancer trial - MSN
(ALKS) On The My Stocks Page - news.stocktradersdaily.com
Alkermes Gains Momentum With Promising Narcolepsy Drug - Finimize
1.34%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):